Want to see JP:4502 full AI Analyst Report?
Takeda Pharmaceutical Co (4502) Ratios
10 Followers
Takeda Pharmaceutical Co Ratios
JP:4502's free cash flow for Q2 2026 was ¥213.19B. For the 2026 fiscal year, JP:4502's free cash flow was decreased by ¥-44.69B and operating cash flow was ¥257.88B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 1.01 | 1.11 | 0.97 | 1.21 |
| Quick Ratio | 0.70 | 0.52 | 0.58 | 0.57 | 0.81 |
| Cash Ratio | 0.24 | 0.09 | 0.09 | 0.09 | 0.40 |
| Solvency Ratio | 0.12 | 0.12 | 0.11 | 0.13 | 0.11 |
| Operating Cash Flow Ratio | 0.39 | 0.38 | 0.28 | 0.35 | 0.48 |
| Short-Term Operating Cash Flow Coverage | 1.83 | 1.57 | 1.48 | 2.20 | 3.96 |
| Net Current Asset Value | ¥ -4.59T | ¥ -4.79T | ¥ -5.28T | ¥ -5.21T | ¥ -4.90T |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.36 | 0.36 | 0.35 | 0.37 |
| Debt-to-Equity Ratio | 0.63 | 0.73 | 0.75 | 0.77 | 0.85 |
| Debt-to-Capital Ratio | 0.39 | 0.42 | 0.43 | 0.43 | 0.46 |
| Long-Term Debt-to-Capital Ratio | 0.36 | 0.36 | 0.38 | 0.39 | 0.42 |
| Financial Leverage Ratio | 1.99 | 2.05 | 2.08 | 2.20 | 2.32 |
| Debt Service Coverage Ratio | 1.46 | 1.33 | 1.74 | 2.10 | 2.43 |
| Interest Coverage Ratio | 1.51 | 3.36 | 3.46 | 4.83 | 4.31 |
| Debt to Market Cap | 0.55 | 0.66 | 0.75 | 0.66 | 0.80 |
| Interest Debt Per Share | 3326.48 | 3341.35 | 3590.41 | 3220.81 | 3167.49 |
| Net Debt to EBITDA | 3.20 | 4.31 | 5.67 | 3.91 | 3.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.06% | 53.59% | 54.53% | 57.07% | 57.26% |
| EBIT Margin | 13.71% | 7.99% | 4.69% | 12.91% | 12.88% |
| EBITDA Margin | 29.72% | 24.61% | 21.76% | 29.41% | 29.22% |
| Operating Profit Margin | 11.99% | 13.70% | 12.46% | 16.34% | 17.11% |
| Pretax Profit Margin | 5.77% | 3.82% | 1.24% | 9.31% | 8.48% |
| Net Profit Margin | 4.26% | 2.36% | 3.38% | 7.87% | 6.45% |
| Continuous Operations Profit Margin | 4.26% | 2.36% | 3.38% | 7.87% | 6.45% |
| Net Income Per EBT | 73.70% | 61.64% | 272.90% | 84.52% | 76.03% |
| EBT Per EBIT | 48.14% | 27.90% | 9.93% | 56.98% | 49.56% |
| Return on Assets (ROA) | 1.24% | 0.76% | 0.95% | 2.27% | 1.75% |
| Return on Equity (ROE) | 2.47% | 1.56% | 1.98% | 4.99% | 4.05% |
| Return on Capital Employed (ROCE) | 4.15% | 5.34% | 4.15% | 5.74% | 5.53% |
| Return on Invested Capital (ROIC) | 2.95% | 3.14% | 4.02% | 4.69% | 4.11% |
| Return on Tangible Assets | 3.08% | 2.04% | 2.66% | 6.47% | 4.65% |
| Earnings Yield | 2.15% | 1.55% | 2.21% | 4.70% | 4.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.14 | 6.32 | 6.11 | 5.91 | 4.93 |
| Payables Turnover | 4.49 | 6.89 | 6.06 | 5.62 | 5.15 |
| Inventory Turnover | 1.58 | 1.75 | 1.60 | 1.75 | 1.79 |
| Fixed Asset Turnover | 2.12 | 2.33 | 2.14 | 2.38 | 2.25 |
| Asset Turnover | 0.29 | 0.32 | 0.28 | 0.29 | 0.27 |
| Working Capital Turnover Ratio | 13.34 | 35.22 | 52.80 | 22.13 | 5.14 |
| Cash Conversion Cycle | 220.84 | 213.80 | 227.25 | 205.11 | 207.42 |
| Days of Sales Outstanding | 70.99 | 57.78 | 59.72 | 61.78 | 74.08 |
| Days of Inventory Outstanding | 231.17 | 208.96 | 227.76 | 208.23 | 204.15 |
| Days of Payables Outstanding | 81.33 | 52.95 | 60.23 | 64.90 | 70.81 |
| Operating Cycle | 302.16 | 266.74 | 287.48 | 270.01 | 278.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 595.98 | 609.61 | 409.29 | 565.29 | 653.16 |
| Free Cash Flow Per Share | 484.24 | 482.43 | 297.17 | 474.65 | 574.33 |
| Dividend Paid and CapEx Coverage Ratio | 1.92 | 1.91 | 1.38 | 2.09 | 2.51 |
| Capital Expenditure Coverage Ratio | 5.33 | 4.79 | 3.65 | 6.24 | 8.29 |
| Operating Cash Flow Coverage Ratio | 0.19 | 0.19 | 0.12 | 0.18 | 0.21 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.21 | 0.15 | 0.22 | 0.29 |
| Free Cash Flow Yield | 8.55% | 10.93% | 7.15% | 10.91% | 16.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 46.52 | 64.56 | 45.16 | 21.29 | 23.77 |
| Price-to-Sales (P/S) Ratio | 1.98 | 1.52 | 1.53 | 1.68 | 1.53 |
| Price-to-Book (P/B) Ratio | 1.15 | 1.00 | 0.89 | 1.06 | 0.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 11.70 | 9.15 | 14.00 | 9.16 | 6.09 |
| Price-to-Operating Cash Flow Ratio | 9.50 | 7.24 | 10.16 | 7.70 | 5.36 |
| Price-to-Earnings Growth (PEG) Ratio | 0.60 | -2.51 | -0.82 | 0.55 | -0.61 |
| Enterprise Value Multiple | 9.86 | 10.49 | 12.68 | 9.61 | 9.04 |
| Enterprise Value | 13.21T | 11.82T | 11.76T | 11.38T | 9.43T |
| EV to EBITDA | 9.86 | 10.49 | 12.68 | 9.61 | 9.04 |
| EV to Sales | 2.93 | 2.58 | 2.76 | 2.83 | 2.64 |
| EV to Free Cash Flow | 17.32 | 15.52 | 25.31 | 15.45 | 10.50 |
| EV to Operating Cash Flow | 14.07 | 12.28 | 18.37 | 12.98 | 9.23 |
| Tangible Book Value Per Share | -922.86 | -1279.40 | -1540.95 | -1743.58 | -1626.33 |
| Shareholders’ Equity Per Share | 4935.42 | 4392.43 | 4649.09 | 4094.65 | 3634.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.26 | 0.38 | -1.73 | 0.15 | 0.24 |
| Revenue Per Share | 2860.66 | 2901.79 | 2725.41 | 2595.34 | 2282.70 |
| Net Income Per Share | 121.75 | 68.36 | 92.09 | 204.29 | 147.14 |
| Tax Burden | 0.74 | 0.62 | 2.73 | 0.85 | 0.76 |
| Interest Burden | 0.42 | 0.48 | 0.26 | 0.72 | 0.66 |
| Research & Development to Revenue | 0.15 | 0.16 | 0.17 | 0.16 | 0.15 |
| SG&A to Revenue | 0.24 | 0.24 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 4.90 | 8.92 | 4.44 | 2.77 | 4.44 |
Currency in JPY
